Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review

Sarah B Doernberg; Cesar A Arias; Deena R Altman; Ahmed Babiker; Helen W Boucher; C Buddy Creech; Sara E Cosgrove; Scott R Evans; Vance G Fowler; Stephanie A Fritz; Toshimitsu Hamasaki; Brendan J Kelly; Sixto M Leal; Catherine Liu; Thomas P Lodise; Loren G Miller; Jose M Munita; Barbara E Murray; Melinda M Pettigrew; Felicia Ruffin; Marc H Scheetz; Bo Shopsin; Truc T Tran; Nicholas A Turner; Derek J Williams; Smitha Zaharoff; Thomas L Holland; Antibacterial Resistance Leadership Group

doi:10.1093/cid/ciad565

Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review

Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S295-S304. doi: 10.1093/cid/ciad565.

Authors

Sarah B Doernberg¹, Cesar A Arias^{2

3

4}, Deena R Altman^{5

6}, Ahmed Babiker^{7

8}, Helen W Boucher⁹, C Buddy Creech^{10

11}, Sara E Cosgrove¹², Scott R Evans¹³, Vance G Fowler¹⁴, Stephanie A Fritz¹⁵, Toshimitsu Hamasaki¹⁶, Brendan J Kelly¹⁷, Sixto M Leal¹⁸, Catherine Liu^{19

20}, Thomas P Lodise²¹, Loren G Miller^{22

23}, Jose M Munita^{24

25}, Barbara E Murray²⁶, Melinda M Pettigrew²⁷, Felicia Ruffin¹⁴, Marc H Scheetz²⁸, Bo Shopsin^{29

30}, Truc T Tran³, Nicholas A Turner¹⁴, Derek J Williams³¹, Smitha Zaharoff³², Thomas L Holland¹⁴; Antibacterial Resistance Leadership Group

Collaborators

Antibacterial Resistance Leadership Group:
Robin Patel, Heather King, Tori Kinamon, Weixiao Dai, Holly Geres, Nancie Deckard, Carl Schuler, Ivra Bunn, Shrabani Sharma, Cathy Wickward, Jason Waller, Holly Wilson, Maureen Mehigan, Varduhi Ghazaryan, Erica Raterman, Tamika Samuel, Marina Lee

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, University of California, SanFrancisco, California, USA.
² Division of Infectious Diseases, Department of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
³ Center for Infectious Diseases, Houston Methodist Research Institute, Houston, Texas, USA.
⁴ Department of Medicine, Weill-Cornell Medical College, New York, New York, USA.
⁵ Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
⁶ Department of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai, NewYork, New York, USA.
⁷ Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
⁸ Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
⁹ Tufts University School of Medicine, Medford, Massachusetts, USA.
¹⁰ Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
¹¹ Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
¹² Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
¹³ Department of Biostatistics, George Washington University, Washington, District of Columbia, USA.
¹⁴ Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
¹⁵ Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA.
¹⁶ Biostatistics Center, George Washington University, Rockville, Maryland, USA.
¹⁷ Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹⁸ Department of Laboratory Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
¹⁹ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
²⁰ Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
²¹ Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA.
²² Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
²³ Division of Infectious Diseases, Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
²⁴ Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clinica Alemana, Universidad del Desarrollo, Santiago, Chile.
²⁵ Multidisciplinary Initiative for Collaborative Research on Bacterial Resistance, Santiago, Chile.
²⁶ Division of Infectious Diseases, Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, USA.
²⁷ Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
²⁸ Pharmacometrics Center of Excellence, College of Pharmacy, Midwestern University, Downers Grove, Illinois, USA.
²⁹ Division of Infectious Diseases, Department of Medicine, New York University Grossman School of Medicine, New York, New York, USA.
³⁰ Department of Microbiology, NewYork University Grossman School of Medicine, New York, New York, USA.
³¹ Division of Hospital Medicine, Department of Pediatrics, Vanderbilt University School of Medicine and the Monroe Carell Jr Children's Hospital at Vanderbilt University Medical Center, Nashville, Tennessee, USA.
³² Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.

Abstract

The Antibacterial Resistance Leadership Group (ARLG) has prioritized infections caused by gram-positive bacteria as one of its core areas of emphasis. The ARLG Gram-positive Committee has focused on studies responding to 3 main identified research priorities: (1) investigation of strategies or therapies for infections predominantly caused by gram-positive bacteria, (2) evaluation of the efficacy of novel agents for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci, and (3) optimization of dosing and duration of antimicrobial agents for gram-positive infections. Herein, we summarize ARLG accomplishments in gram-positive bacterial infection research, including studies aiming to (1) inform optimal vancomycin dosing, (2) determine the role of dalbavancin in MRSA bloodstream infection, (3) characterize enterococcal bloodstream infections, (4) demonstrate the benefits of short-course therapy for pediatric community-acquired pneumonia, (5) develop quality of life measures for use in clinical trials, and (6) advance understanding of the microbiome. Future studies will incorporate innovative methodologies with a focus on interventional clinical trials that have the potential to change clinical practice for difficult-to-treat infections, such as MRSA bloodstream infections.

Keywords: antibacterial agents; antibacterial resistance; gram-positive bacterial infections; methicillin-resistant Staphylococcus aureus; vancomycin-resistant enterococci.

Publication types

Review
Research Support, N.I.H., Extramural

MeSH terms

Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use
Child
Gram-Positive Bacteria
Gram-Positive Bacterial Infections* / drug therapy
Gram-Positive Bacterial Infections* / microbiology
Humans
Leadership
Methicillin-Resistant Staphylococcus aureus*
Quality of Life
Sepsis* / drug therapy

Substances

Anti-Bacterial Agents

Abstract

Publication types

MeSH terms

Substances

Grants and funding